Oncology & Cancer

Study validates therapy for aggressive bladder cancer

Findings from a new study led by Yale Cancer Center researchers show enfortumab vedotin is effective in patients with muscle-invasive bladder cancer (MIBC) not eligible for cisplatin chemotherapy. The data is from Cohort ...

page 6 from 38